Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.14 USD
-0.07 (-5.79%)
Updated Sep 25, 2024 03:16 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Nektar Therapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 304 | 505 | 734 | 1,062 | 1,325 |
Receivables | 1 | 6 | 22 | 39 | 37 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 19 | 16 | 15 | 13 |
Other Current Assets | 10 | 16 | 23 | 22 | 47 |
Total Current Assets | 331 | 546 | 796 | 1,138 | 1,422 |
Net Property & Equipment | 19 | 32 | 61 | 60 | 65 |
Investments & Advances | 26 | 0 | 65 | 137 | 279 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 77 | 77 | 77 | 77 |
Deposits & Other Assets | 5 | 2 | 3 | 1 | 1 |
Total Assets | 398 | 711 | 1,117 | 1,539 | 1,977 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 13 | 10 | 22 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 249 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 37 | 58 | 80 | 67 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 6 |
Total Current Liabilities | 51 | 68 | 85 | 116 | 354 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 2 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 117 | 163 | 227 | 207 | 73 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 267 | 344 | 438 | 461 | 572 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,608 | 3,575 | 3,517 | 3,389 | 3,271 |
Retained Earnings | -3,477 | -3,201 | -2,833 | -2,309 | -1,865 |
Other Equity | 0 | -7 | -4 | -2 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 131 | 367 | 680 | 1,077 | 1,405 |
Total Liabilities & Shareholder's Equity | 398 | 711 | 1,117 | 1,539 | 1,977 |
Total Common Equity | 131 | 367 | 680 | 1,077 | 1,405 |
Shares Outstanding | 190.70 | 187.90 | 184.50 | 179.40 | 175.90 |
Book Value Per Share | 0.69 | 1.95 | 3.68 | 6.01 | 7.99 |
Fiscal Year End for Nektar Therapeutics falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 271 | 289 | 304 | 373 | 409 |
Receivables | 1 | 4 | 1 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 14 | 16 | 16 | 15 | 21 |
Other Current Assets | 8 | 11 | 10 | 9 | 10 |
Total Current Assets | 295 | 320 | 331 | 399 | 441 |
Net Property & Equipment | 15 | 17 | 19 | 20 | 23 |
Investments & Advances | 19 | 37 | 26 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 5 | 5 | 5 | 2 |
Total Assets | 343 | 396 | 398 | 442 | 494 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 9 | 10 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 30 | 24 | 22 | 30 | 29 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 57 | 52 | 51 | 52 | 51 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 116 | 117 | 129 | 141 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 264 | 269 | 267 | 283 | 297 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 3,650 | 3,644 | 3,608 | 3,601 | 3,593 |
Retained Earnings | -3,566 | -3,514 | -3,477 | -3,435 | -3,389 |
Other Equity | 0 | 0 | 0 | -6 | -6 |
Treasury Stock | 3 | 3 | 0 | 0 | 0 |
Total Shareholder's Equity | 80 | 127 | 131 | 159 | 197 |
Total Liabilities & Shareholder's Equity | 343 | 396 | 398 | 442 | 494 |
Total Common Equity | 80 | 127 | 131 | 159 | 197 |
Shares Outstanding | 184.00 | 183.60 | 190.70 | 190.10 | 189.20 |
Book Value Per Share | 0.43 | 0.69 | 0.69 | 0.84 | 1.04 |